Emerging Technologies Guide: Fall 2025
Recent new and emerging technologies in the field of laboratory medicine from the 2025 September Pathogen Detection & Infectious Disease issue of Today's Clinical Lab
Today’s Clinical Lab is a reader-centric publication that keeps clinical professionals up to date with today’s rapidly changing lab industry with in-depth and timely editorial content and resources, including clinical industry news and insights into the latest trends, technologies, and techniques in the clinical lab.
ViewFull ProfileLearn about ourEditorial Policies.
The rapid and widespread emergence of extended-spectrum beta-lactamases (ESBLs) is a growing global health concern. Now, a breakthrough lateral flow assay distributed in the US by Hardy Diagnostics called NG-TEST® CTX-M Multi, rapidly confirms the presence of CTX-M enzymes in minutes, not hours. In just 15 minutes, the FDA-cleared NG-TEST® CTX-M Multi will provide qualitative detection of most prevalent CTX-M enzymes from pure colonies of Enterobacterales suspected of ESBL production.
INTEGRA Biosciences’ automated liquid handling solutions and pipetting software are supporting 3T Biosciences—a California-based biotech company—in the search for novel cancer treatments, enhancing the reproducibility and productivity of pipetting workflows to help accelerate the development of more effective therapeutics.
Successful cell therapies require viable, high-quality cells. The MACSQuant Tyto delivers GMP-compliant, closed-system sorting with unmatched sterility and precision. Now featuring an additional yellow laser, 12-color detection, and integrated temperature control, it drives high-purity cell separation while minimizing stress—maximizing cell viability, functionality, and clinical impact.
The QX Continuum Droplet Digital™ PCR (ddPCR™) System* combines a simple workflow with sensitivity and precision, empowering researchers to explore a wide range of applications. From detecting subtle changes in gene expression to analyzing copy number variations, identifying rare mutations, or achieving absolute quantification, the system delivers reliable results that meet the needs of varied research objectives. Its advanced capabilities eliminate the need for standard curves or extensive training, allowing for seamless integration into existing research workflows and supporting diverse experimental needs. *For Research use only. Not for use in diagnostic procedures.
New Ocus® M 20 Digital Slide Scanner
Grundium
New Ocus® M 20 Digital Slide Scanner
Grundium is the digital pathology innovator behind the Ocus slide scanners. Ocus single-slide scanners have supported the advancement of digital pathology and changed how intraoperative procedures (e.g., frozen sections and ROSE) are done through telepathology. The Ocus M series scanners maintain the same advantages of the original Ocus portfolio—small, fast, reliable, affordable, easy-to-use, unparalleled image quality—while expanding capacity to four slides. The Ocus M 20 is now available. This scanner is built on the same advanced platform as the Ocus M 40 (released in April 2025), however, the new 20x variant is designed for situations where the focus is on speed and efficiency but maximum magnification isn’t needed. The Ocus M series will enable continued expansion and use of digital pathology and AI in your lab.
VivoJect™ Image-Guided Injection System
Revvity
VivoJect™ Image-Guided Injection System
The VivoJect™ Image-Guided Injection System uses real-time imaging to deliver cells or therapies with increased accuracy. Its user-friendly, nimble operation enables higher throughput than traditional techniques. Paired with the Vega™ automated preclinical ultrasound system, the device streamlines in vivo imaging workflows for tumor model creation, targeted drug delivery, gene therapy, stem cell research, and cardiac studies.
For research use only. Not for use in humans, or for diagnostic or therapeutic procedures in animals.